Biochemical efficacy and tolerability of allopurinol, benzbromarone and probenecid in GOUT

Completed

• Conditions: Arthropathies; Musculoskeletal Diseases; Hyperuricemia, gout

• Registration Number: ISRCTN21473387
• Lead Sponsor: Medical Centre Leeuwarden (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-02-26
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 96

Inclusion Criteria

1. Aged greater than 18 years
2. Diagnosis gout based on crystal evidence or American Rheumatism Association (ARA) criteria
3. Eestimated creatinine clearance more than 50 ml/min
4. Baseline values measured: serum urate, urinary urate excretion, serum creatinine

Exclusion Criteria

1. Contra-indication for allopurinol, benzbromaron or probenecid
2. Prior treatment with allopurinol, benzbromaron or probenecid

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Success rate on study medication consisting of patient tolerability and attainment of target level serum urate less than 0.30 mmol/l after eight weeks treatment.

Secondary Outcome Measures

Name	Time	Method
1. Serum urate lowering effect (% decrease) of the antihyperuricemic agent<br>2. Tolerability of the antihyperuricemic agent (adverse drug reactions)